Murakami Akira
Forum Nutr. 2009;61:193-203. doi: 10.1159/000212751. Epub 2009 Apr 7.
A regulated low level of nitric oxide (NO) production in the body is essential for maintaining homeostasis (neuroprotection, vasorelaxation, etc.), though certain pathophysiological conditions associated with inflammation involve de novo synthesis of inducible NO synthase (iNOS) in immune cells, including macrophages. A large body of evidence indicates that many inflammatory diseases, such as colitis and gastritis, as well as many types of cancer, occur through sustained and elevated activation of this particular enzyme. The biochemical process of iNOS protein expression is tightly regulated and complex, in which the endotoxin lipopolysaccharide selectively binds to toll-like receptor 4 and thereby activates its adaptor protein MyD88, which in turn targets downstream proteins such as IRAK and TRAF6. This leads to functional activation of key protein kinases, including IkB kinases and mitogen-activated protein kinases (MAPKs), such as p38 MAPK, JNK1/2, and ERK1/2, all of which are involved in activating key transcription factors, including nuclear factor-kappaB and activator protein-1. In addition, the production of proinflammatory cytokines such as interferon-gamma and interleukin-12 potentiates iNOS induction in autocrine fashions. Meanwhile, an LPS-stimulated p38 MAPK pathway plays a pivotal role in the stabilization of iNOS mRNA, which has the AU-rich element in its 3'-untranslated region, for rapid NO production. Thus, suppression and/or inhibition of the above-mentioned signaling molecules may have a great potential for the prevention and treatment of inflammation-associated carcinogenesis. In fact, there have been numerous reports of phytochemicals found capable of targeting NO production by unique mechanisms, including polyphenols, terpenoids, and others. This review article briefly highlights the molecular mechanisms underlying endotoxin-induced iNOS expression in macrophages, and also focuses on promising natural agents that may be useful for anti-inflammation and anticarcinogenesis strategies.
体内一氧化氮(NO)产生水平受到调节处于低水平,这对于维持体内平衡(神经保护、血管舒张等)至关重要,尽管某些与炎症相关的病理生理状况涉及免疫细胞(包括巨噬细胞)中诱导型一氧化氮合酶(iNOS)的从头合成。大量证据表明,许多炎症性疾病,如结肠炎和胃炎,以及许多类型的癌症,都是通过这种特定酶的持续和过度激活而发生的。iNOS蛋白表达的生化过程受到严格调控且复杂,其中内毒素脂多糖选择性结合Toll样受体4,从而激活其衔接蛋白MyD88,MyD88进而靶向下游蛋白,如IRAK和TRAF6。这导致关键蛋白激酶的功能激活,包括IkB激酶和丝裂原活化蛋白激酶(MAPK),如p38 MAPK、JNK1/2和ERK1/2,所有这些激酶都参与激活关键转录因子,包括核因子-κB和活化蛋白-1。此外,促炎细胞因子如干扰素-γ和白细胞介素-12的产生以自分泌方式增强iNOS的诱导。同时,LPS刺激的p38 MAPK途径在iNOS mRNA的稳定中起关键作用,iNOS mRNA在其3'非翻译区具有富含AU的元件,以实现快速产生NO。因此,抑制上述信号分子可能对预防和治疗炎症相关的致癌作用具有巨大潜力。事实上,已有许多关于植物化学物质能够通过独特机制靶向NO产生的报道,包括多酚、萜类化合物等。本文简要强调了内毒素诱导巨噬细胞中iNOS表达的分子机制,并重点关注了可能用于抗炎和抗癌策略的有前景的天然药物。